Thrombosis research · 2025
tPA-ROTEM identifies hyperfibrinolytic profile in a significant proportion of patients with bleeding disorder of unknown cause (BDUC).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Monard A L L, Hellenbrand D, Verhezen P, Beckers E A M, Henskens Y C M, Heubel-Moenen F C J I
Аннотация
BACKGROUND: In the majority of patients referred for evaluation of bleeding symptoms, no diagnosis can be made after extensive laboratory testing. These patients are classified as having a bleeding disorder of unknown cause (BDUC). Little is known about the role of the fibrinolytic pathway in BDUC patients.
AIM: To investigate the capacity of the tPA-ROTEM assay to detect fibrinolytic abnormalities in BDUC patients and to correlate these findings with fibrinolytic protein activity levels.
METHODS: Patients with an increased bleeding tendency were included in a prospective cohort study. BDUC patients were identified based on an increased bleeding tendency and no abnormalities in extensive laboratory testing. The tPA-ROTEM assay was performed and plasma levels of PAI-1 activity and antigen, α2-antiplasmin, tPA antigen and TAFI were measured using ELISA assays. Pre-specified definitions of hyper- and hypofibrinolysis were applied.
RESULTS: tPA-ROTEM identified a hyperfibrinolytic profile in 19/92 (21 %) of BDUC patients. Multivariable regression analysis showed that lower PAI-1 antigen levels were independently associated with hyperfibrinolysis.
CONCLUSION: tPA-ROTEM identified a hyperfibrinolytic profile in 21 % of BDUC patients. These findings suggest that antifibrinolytic medications may be useful to control bleeding or prevent bleeding in surgical interventions in a group of patients with BDUC.
AIM: To investigate the capacity of the tPA-ROTEM assay to detect fibrinolytic abnormalities in BDUC patients and to correlate these findings with fibrinolytic protein activity levels.
METHODS: Patients with an increased bleeding tendency were included in a prospective cohort study. BDUC patients were identified based on an increased bleeding tendency and no abnormalities in extensive laboratory testing. The tPA-ROTEM assay was performed and plasma levels of PAI-1 activity and antigen, α2-antiplasmin, tPA antigen and TAFI were measured using ELISA assays. Pre-specified definitions of hyper- and hypofibrinolysis were applied.
RESULTS: tPA-ROTEM identified a hyperfibrinolytic profile in 19/92 (21 %) of BDUC patients. Multivariable regression analysis showed that lower PAI-1 antigen levels were independently associated with hyperfibrinolysis.
CONCLUSION: tPA-ROTEM identified a hyperfibrinolytic profile in 21 % of BDUC patients. These findings suggest that antifibrinolytic medications may be useful to control bleeding or prevent bleeding in surgical interventions in a group of patients with BDUC.